December 26, 2014 10:57 AM ET

Biotechnology

Company Overview of OPKO Biologics

Company Overview

OPKO Biologics, a development stage biopharmaceutical company, is engaged in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide (CTP) is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company’s products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development als...

7 Golda Meir Street

Weizmann Science Park

Nes-Ziona,  74140

Israel

25 Employees

Phone:

866 644 7811

Fax:

972 8 930 0091

Key Executives for OPKO Biologics

Chief Executive Officer and Director
Age: 66
President
Age: 48
Chief Financial Officer and Principal Accounting Officer
Age: 64
Chief Operating Officer of Prolor Biotech Ltd
Age: 49
Director and Chief Scientific Officer of Prolor Biotech Ltd
Age: 59
Compensation as of Fiscal Year 2014.

OPKO Biologics Key Developments

PROLOR Biotech, Inc.(TASE:PBTH) dropped from TA-100 Index

PROLOR Biotech, Inc. will be removed from TA-100 Index.

PROLOR Biotech, Inc., Special/Extraordinary Shareholders Meeting, Aug 28, 2013

PROLOR Biotech, Inc., Special/Extraordinary Shareholders Meeting, Aug 28, 2013.

PROLOR Biotech, Inc. to Present Positive Results from Preclinical Studies of Long-Acting Clotting Factor VIIa-CTP at ISTH 2013

PROLOR Biotech, Inc. announced that the company will present new results from preclinical studies of its long-acting clotting factor VIIa (Factor VIIa-CTP), a next-generation investigational therapy in advanced preclinical development for the potential treatment of hemophilia. The data provide further evidence that Factor VIIa-CTP has the potential to be administered by subcutaneous (SC) injection as well as intravenously (IV), which would facilitate its prophylactic use by patients on an ongoing basis. The study results will be discussed in an oral presentation at the XXIV Congress of the International Society of Hemostasis and Thrombosis (ISTH). Currently available commercial factor VIIa must be administered through IV infusion, which can be onerous for patients. This limits its use for prophylactic treatment and can require frequent administrations if patients are treated only "on demand" when a bleeding episode occurs. The new preclinical results being presented at the ISTH Congress further confirm the efficacy of PROLOR's long-acting Factor VIIa-CTP and show that it has the potential to be administered using a simple SC injection. The combination of a long-acting product coupled with the ability to be administered by SC injection could change the way that factor VIIa is used, potentially allowing individuals with hemophilia to self-administer the drug at home on a prophylactic basis, improving their quality of life and potentially reducing the need for on-demand treatment of bleeding episodes.

Similar Private Companies By Industry

Company Name Region
JPMed Ltd. Middle East/Africa
Regentis Biomaterials Ltd. Middle East/Africa
Econaf Ltd Middle East/Africa
UC Care Ltd. Middle East/Africa
One World Cannabis Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OPKO Biologics, please visit www.prolor-biotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.